Gilead bags blood disorder drug with YM BioSciences buy

Thu Dec 13, 2012 4:26am IST

Related Topics

Stocks

   

(Reuters) - Gilead Sciences Inc said it would buy Canada's YM BioSciences Inc for about $510 million in cash, getting access to a second experimental drug to treat a rare blood and immune cell disorder.

Gilead shares closed down 0.14 percent at $76.23 on the Nasdaq, while YM's U.S.-listed shares closed up 77 percent at $2.88, just under Gilead's offer price.

YM's only drug, codenamed CYT387, is being tested in patients with myelofibrosis, a blood disorder with limited treatment options.

Gilead, which is conducting mid-stage trials of its own drug for the disorder, said it will begin a pivotal late-stage clinical trial of CYT387 in the second half of 2013.

Shares of Incyte Corp, which sells the only approved drug to treat myelofibrosis, closed down 6 percent at $16.75 on news of Gilead's deal with YM.

Incyte received $43.7 million from the sale of the drug, Jakafi, in the United States during July-September.

YM took hold of CYT387 with its acquisition of the Australian biopharmaceutical company Cytopia Ltd in 2010.

"It's a good outcome for YM because they bought the product for a relatively modest amount, and a good fit for Gilead's strategy of broadening its portfolio particularly in oncology," Edison Investment Research analyst Christian Glennie said.

Gilead said it will pay $2.95 per YM share and that it plans to fund the acquisition with cash on hand. The deal would be valued at about $465 million based on YM's outstanding shares, excluding options.

As of September 30, YM had cash and short-term deposits of C$125.5 million ($127 million), according to a filing.

"While the valuation is less than the $4-$5 fair value we had assumed for YM, ... there is a relatively low probability another party enters with a higher bid," Wells Fargo Securities analyst Brian Abrahams said in a note to clients.

The transaction is expected to close in the first quarter of 2013.

BofA Merrill Lynch and Bloom Burton & Co were financial advisers of YM, while Gilead was advised by Wilson Sonsini Goodrich & Rosati and Blake Cassels and Graydon LLP.

($1 = 0.9852 Canadian dollars)

(Reporting by Adithya Venkatesan and Shounak Dasgupta in Bangalore; Editing by Roshni Menon, Don Sebastian, Maju Samuel)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Ebola Outbreak

REUTERS SHOWCASE

Change Of Venue

Change Of Venue

Parks, playgrounds offer fresh air alternatives to gym workouts.  Full Article 

Antibiotics Quest

Antibiotics Quest

Extreme medicine: The search for new antibiotics.  Full Article 

Biotech Drugs

Biotech Drugs

'Plantibodies' drugs advance as big pharma stands aside.  Full Article 

Promising Vaccine

Promising Vaccine

Experimental chikungunya vaccine shows promise in human trial.  Full Article 

No Unanimity

No Unanimity

Even dentists differ on the best tooth-brushing method.  Full Article 

Importance Of Religion

Importance Of Religion

Religiosity associated with less depression in elderly: study.  Full Article 

Changing Demographic

Changing Demographic

From cradle to grave, Japan's Kewpie adapts menu to feed ageing nation.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage